{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:14:03Z","timestamp":1789492443776,"version":"build-2803163510"},"reference-count":127,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jhep.2026.06.037","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T20:24:37Z","timestamp":1784838277000},"page":"740-752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pushing the boundaries of liver resection for liver cancer"],"prefix":"10.1016","volume":"85","author":[{"given":"Gonzalo","family":"Sapisochin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8690-403X","authenticated-orcid":false,"given":"Grainne M.","family":"O\u2019Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5050-8967","authenticated-orcid":false,"given":"Anudari","family":"Zorigtbaatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert Chi","family":"Yan Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherrie","family":"Bhoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2026.06.037_bib1","article-title":"Comparisons of global incidence and risk factor profiles of hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"31","author":"Wu","year":"2025","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2026.06.037_bib2","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/bjs\/znad233","article-title":"E-AHPBA-ESSO-ESSR Innsbruck consensus guidelines for preoperative liver function assessment before hepatectomy","volume":"110","author":"Primavesi","year":"2023","journal-title":"Br J Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib3","doi-asserted-by":"crossref","DOI":"10.5492\/wjccm.v13.i2.92751","article-title":"Major liver resections, perioperative issues and posthepatectomy liver failure: a comprehensive update for the anesthesiologist","volume":"13","author":"De Gasperi","year":"2024","journal-title":"World J Crit Care Med"},{"key":"10.1016\/j.jhep.2026.06.037_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrac097","article-title":"Impact of post-hepatectomy liver failure on morbidity and short- and long-term survival after major hepatectomy","volume":"6","author":"Baumgartner","year":"2022","journal-title":"BJS Open"},{"key":"10.1016\/j.jhep.2026.06.037_bib5","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1007\/s11605-023-05834-2","article-title":"Postoperative liver failure: definitions, risk factors, prediction models and prevention strategies","volume":"27","author":"Merath","year":"2023","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib6","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jhep.2016.06.006","article-title":"Liver resection for cancer: new developments in prediction, prevention and management of postresectional liver failure","volume":"65","author":"van Mierlo","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.06.037_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.06.037_bib8","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.06.037_bib9","article-title":"The ALBI score: from liver function in patients with HCC to a general measure of liver function","volume":"4","author":"Toyoda","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2026.06.037_bib10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.amjsurg.2022.07.028","article-title":"Performance of risk prediction models for post-operative mortality in patients undergoing liver resection","volume":"225","author":"Mahmud","year":"2023","journal-title":"Am J Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib11","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1001\/archsurg.138.11.1198","article-title":"One thousand fifty-six hepatectomies without mortality in 8 years","volume":"138","author":"Imamura","year":"2003","journal-title":"Arch Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib12","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.hpb.2023.06.001","article-title":"Joint EANM\/SNMMI\/IHPBA procedure guideline for [(99m)Tc]Tc-mebrofenin hepatobiliary scintigraphy SPECT\/CT in the quantitative assessment of the future liver remnant function","volume":"25","author":"Arntz","year":"2023","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jhep.2026.06.037_bib13","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.hpb.2021.04.014","article-title":"Variations between the anatomical and functional distribution, based on 99(m) technetium -mebrofinate SPECT-CT scan, in patients at risk of post hepatectomy liver failure","volume":"23","author":"Dasari","year":"2021","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jhep.2026.06.037_bib14","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.gassur.2024.02.020","article-title":"Liver volumetry and liver-regenerative interventions: history, rationale, and emerging tools","volume":"28","author":"Haddad","year":"2024","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib15","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jhep.2013.06.015","article-title":"Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection","volume":"59","author":"Vouche","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.06.037_bib16","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0016-5085(96)70070-7","article-title":"Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure","volume":"111","author":"Bruix","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.06.037_bib17","article-title":"New frontiers in liver resection for hepatocellular carcinoma","volume":"2","author":"Allaire","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2026.06.037_bib18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jhep.2011.06.027","article-title":"Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors","volume":"56","author":"Llop","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.06.037_bib19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/SLA.0000000000006185","article-title":"The impact of portal hypertension assessment method on the outcomes of hepatocellular carcinoma resection: a meta-analysis of matched cohort and prospective studies","volume":"280","author":"Aliseda","year":"2024","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1245\/s10434-023-14376-5","article-title":"Impact of liver cirrhosis, severity of cirrhosis, and portal hypertension on the difficulty and outcomes of laparoscopic and robotic major liver resections for primary liver malignancies","volume":"31","author":"Cipriani","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13133869","article-title":"The effects of sarcopenia on overall survival and postoperative complications of patients undergoing hepatic resection for primary or metastatic liver cancer: a systematic review and meta-analysis","volume":"13","author":"Giakoustidis","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jhep.2026.06.037_bib22","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.32049","article-title":"Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases","volume":"74","author":"Lai","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.06.037_bib23","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/jamasurg.2016.1121","article-title":"Hierarchic interaction of factors associated with liver decompensation after resection for hepatocellular carcinoma","volume":"151","author":"Citterio","year":"2016","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib24","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s12072-024-10644-y","article-title":"Surgical risk stratification in patients with cirrhosis","volume":"18","author":"Ostojic","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2026.06.037_bib25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","article-title":"Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients","volume":"71","author":"Cabibbo","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.06.037_bib26","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ejso.2020.11.310","article-title":"Is laparoscopic liver resection safe for intrahepatic cholangiocarcinoma? A meta-analysis","volume":"47","author":"Regmi","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/00365521.2022.2143724","article-title":"Laparoscopic versus open liver resection for intrahepatic cholangiocarcinoma: a multicenter propensity score-matched study","volume":"58","author":"Sahakyan","year":"2023","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2026.06.037_bib28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ijsu.2020.05.008","article-title":"Anatomic versus non-anatomic resection for hepatocellular carcinoma, do we have an answer? A meta-analysis","volume":"80","author":"Jiao","year":"2020","journal-title":"Int J Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib29","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ejso.2018.04.018","article-title":"Anatomic versus non-anatomic resection for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"44","author":"Moris","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib30","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1097\/JS9.0000000000000503","article-title":"Effect of anatomical liver resection for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"109","author":"Shin","year":"2023","journal-title":"Int J Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12957-023-03004-x","article-title":"Safety and feasibility of laparoscopic liver resection for intrahepatic cholangiocarcinoma: a propensity score-matched study","volume":"21","author":"Shen","year":"2023","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib32","doi-asserted-by":"crossref","first-page":"584","DOI":"10.5582\/bst.2024.01277","article-title":"Laparoscopic versus open liver resection for intrahepatic cholangiocarcinoma: stratified analysis based on tumor burden score","volume":"18","author":"Li","year":"2025","journal-title":"Biosci Trends"},{"key":"10.1016\/j.jhep.2026.06.037_bib33","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/ags3.12817","article-title":"Essential updates 2022\/2023: a review of current topics in robotic hepatectomy","volume":"8","author":"Adachi","year":"2024","journal-title":"Ann Gastroenterol Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib34","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1007\/s00268-021-06115-2","article-title":"Laparoscopic versus open liver resection for hepatocellular carcinoma: a case controlled study with propensity score matching","volume":"45","author":"Uemoto","year":"2021","journal-title":"World J Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2022.101790","article-title":"Short- and long-term outcomes following robotic and open resection for intrahepatic cholangiocarcinoma: a national cohort study","volume":"43","author":"Hamad","year":"2022","journal-title":"Surg Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib36","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.ejso.2017.02.012","article-title":"The role of minimally invasive surgery in the treatment of cholangiocarcinoma","volume":"43","author":"Levi Sandri","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib37","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1177\/00031348221093933","article-title":"Analysis of oncological outcomes after robotic liver resection for intrahepatic cholangiocarcinoma","volume":"89","author":"Shapera","year":"2023","journal-title":"Am Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znaf113","article-title":"The Brescia internationally validated European guidelines on minimally invasive liver surgery","volume":"112","author":"Abu Hilal","year":"2025","journal-title":"Br J Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib39","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamasurg.2022.5697","article-title":"Safety and efficacy of robotic vs open liver resection for hepatocellular carcinoma","volume":"158","author":"Di Benedetto","year":"2023","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib40","article-title":"Robotic, laparoscopic, and open liver resection for hepatocellular carcinoma: a propensity score matched analysis of perioperative outcomes","volume":"14","author":"O'Connell","year":"2023","journal-title":"Surg Pract Sci"},{"key":"10.1016\/j.jhep.2026.06.037_bib41","article-title":"Robotic versus laparoscopic hepatectomy for liver malignancies (ROC'N'ROLL): a single-centre, randomised, controlled, single-blinded clinical trial","volume":"43","author":"Birgin","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jhep.2026.06.037_bib42","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/SLA.0000000000003433","article-title":"ALPPS versus portal vein embolization for hepatitis-related hepatocellular carcinoma: a changing paradigm in modulation of future liver remnant before major hepatectomy","volume":"273","author":"Chan","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12957-021-02199-1","article-title":"Efficacy of the association liver partition and portal vein ligation for staged hepatectomy for the treatment of solitary huge hepatocellular carcinoma: a retrospective single-center study","volume":"19","author":"Deng","year":"2021","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.21037\/hbsn-20-264","article-title":"Associating liver partition and portal vein ligation for staged hepatectomy versus sequential transarterial chemoembolization and portal vein embolization in staged hepatectomy for HBV-related hepatocellular carcinoma: a randomized comparative study","volume":"11","author":"Li","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.jhep.2026.06.037_bib45","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000343829","article-title":"Portal vein embolization for hepatocellular carcinoma","volume":"1","author":"Shindoh","year":"2012","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2026.06.037_bib46","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/SLA.0000000000002942","article-title":"Associating liver partition and portal vein ligation for staged hepatectomy for unresectable hepatitis B virus-related hepatocellular carcinoma: a single center study of 45 patients","volume":"271","author":"Wang","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib47","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1097\/SLA.0000000000000736","article-title":"Simplifying the ALPPS procedure by the anterior approach","volume":"260","author":"Chan","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib48","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.hpb.2025.12.013","article-title":"Associating liver partition and portal vein ligation for staged hepatectomy in patients with hepatocellular carcinoma: laparoscopic versus open approach and its impact on future remnant hypertrophy","volume":"28","author":"Au","year":"2026","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jhep.2026.06.037_bib49","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s13304-023-01680-8","article-title":"Robotic ALPPS for primary and metastatic liver tumours: short-term outcomes versus open approach","volume":"76","author":"Magistri","year":"2024","journal-title":"Updates Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib50","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1245\/s10434-015-5007-0","article-title":"Should ALPPS be used for liver resection in intermediate-stage HCC?","volume":"23","author":"D'Haese","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib51","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/SLA.0000000000005121","article-title":"Liver venous deprivation or associating liver partition and portal vein ligation for staged hepatectomy?: a retrospective multicentric study","volume":"274","author":"Chebaro","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib52","article-title":"Feasibility of personalized and tumor-informed circulating tumor DNA assay for early recurrence detection in patients with hepatocellular carcinoma","volume":"9","author":"Abdelrahim","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib53","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.surg.2021.12.026","article-title":"Prognostic impact of the metastatic lymph node number in intrahepatic cholangiocarcinoma","volume":"172","author":"Kim","year":"2022","journal-title":"Surgery"},{"key":"10.1016\/j.jhep.2026.06.037_bib54","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.hpb.2020.01.009","article-title":"Prognostic significance of and risk prediction model for lymph node metastasis in resectable intrahepatic cholangiocarcinoma: do all require lymph node dissection?","volume":"22","author":"Navarro","year":"2020","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jhep.2026.06.037_bib55","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s11605-017-3652-2","article-title":"Lymphadenectomy for intrahepatic cholangiocarcinoma: has nodal evaluation been increasingly adopted by surgeons over time?A national database analysis","volume":"22","author":"Zhang","year":"2018","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib56","doi-asserted-by":"crossref","first-page":"1031-1040","DOI":"10.1016\/j.jamcollsurg.2015.09.012","article-title":"Intrahepatic cholangiocarcinoma: prognosis of patients who did not undergo lymphadenectomy","volume":"221","author":"Bagante","year":"2015","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib57","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11605-017-3426-x","article-title":"Assessment of the lymph node status in patients undergoing liver resection for intrahepatic cholangiocarcinoma: the new eighth edition AJCC staging system","volume":"22","author":"Bagante","year":"2018","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib58","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.2011.35.6519","article-title":"Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment","volume":"29","author":"de Jong","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib59","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.hpb.2015.07.006","article-title":"Impact of lymph node status in patients with intrahepatic cholangiocarcinoma treated by major hepatectomy: a review of the National Cancer Database","volume":"18","author":"Jutric","year":"2016","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jhep.2026.06.037_bib60","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s13304-024-01852-0","article-title":"A snapshot on current approaches to lymphadenectomy in liver resection for intrahepatic cholangiocarcinoma: results from an international survey","volume":"76","author":"Sposito","year":"2024","journal-title":"Updates Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib61","doi-asserted-by":"crossref","first-page":"52","DOI":"10.21037\/cco.2018.07.03","article-title":"Intrahepatic cholangiocarcinoma: the AJCC\/UICC 8th edition updates","volume":"7","author":"Lee","year":"2018","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib62","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/hpb.12441","article-title":"Intrahepatic cholangiocarcinoma: expert consensus statement","volume":"17","author":"Weber","year":"2015","journal-title":"HPB (Oxford)"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2026.06.037_bib63","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/S0022-510X(09)71300-0","article-title":"The Will Rogers phenomenon: the effect of different diagnostic criteria","volume":"287","author":"Sormani","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jhep.2026.06.037_bib64","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jhep.2022.10.021","article-title":"Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node-negative intrahepatic cholangiocarcinoma","volume":"78","author":"Sposito","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.06.037_bib65","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1158\/1078-0432.CCR-25-3296","article-title":"Excessive dissection of non-metastatic tumor-draining lymph nodes impairs immunotherapy efficacy in recurrent biliary tract cancer","volume":"32","author":"Long","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2026.06.037_bib66","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12672-025-02322-8","article-title":"The optimal number of examined lymph nodes for cancer specific death of intrahepatic cholangiocarcinoma: a population-based study","volume":"16","author":"Ou","year":"2025","journal-title":"Discov Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib67","doi-asserted-by":"crossref","first-page":"e1187","DOI":"10.1097\/SLA.0000000000003788","article-title":"Number and station of lymph node metastasis after curative-intent resection of intrahepatic cholangiocarcinoma impact prognosis","volume":"274","author":"Zhang","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib68","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/hepr.14196","article-title":"Defining advanced lymph node metastasis in intrahepatic cholangiocarcinoma: a multicenter study","volume":"55","author":"Kurimoto","year":"2025","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2026.06.037_bib69","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.hpb.2024.03.1163","article-title":"Is routine lymph node dissection recommended for liver resection of intrahepatic cholangiocarcinoma? A systematic review and meta-analysis","volume":"26","author":"Ishii","year":"2024","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jhep.2026.06.037_bib70","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/jhbp.1038","article-title":"Impact of lymph node dissection on clinical outcomes of intrahepatic cholangiocarcinoma: inverse probability of treatment weighting with survival analysis","volume":"29","author":"Umeda","year":"2022","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.jhep.2026.06.037_bib71","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.hpb.2023.02.013","article-title":"The impact of tumor location on the value of lymphadenectomy for intrahepatic cholangiocarcinoma","volume":"25","author":"Endo","year":"2023","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jhep.2026.06.037_bib72","doi-asserted-by":"crossref","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Vogel","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib73","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2026.06.037_bib74","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.24.00857","article-title":"Liver transplantation for hepatocellular carcinoma: an expanding cornerstone of care in the era of immunotherapy","volume":"43","author":"Magyar","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib75","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/hep4.1923","article-title":"Global and regional long-term survival following resection for HCC in the recent decade: a meta-analysis of 110 studies","volume":"6","author":"Reveron-Thornton","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2026.06.037_bib76","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.jhep.2018.08.027","article-title":"Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection","volume":"69","author":"Chan","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.06.037_bib77","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2026.06.037_bib78","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.2_suppl.477","article-title":"Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: the phase 3 keynote-937 study","volume":"44","author":"Chan","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib79","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib80","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/S0140-6736(25)01720-9","article-title":"Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2\/3 trial","volume":"406","author":"Wang","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2026.06.037_bib81","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/HEP.0000000000000726","article-title":"Adjuvant and neoadjuvant therapies for hepatocellular carcinoma","volume":"82","author":"Vogel","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.06.037_bib82","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1245\/s10434-022-12530-z","article-title":"Hepatectomy after conversion therapy using tyrosine kinase inhibitors plus anti-PD-1 antibody therapy for patients with unresectable hepatocellular carcinoma","volume":"30","author":"Zhu","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib83","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000528356","article-title":"Outcomes of salvage surgery for initially unresectable hepatocellular carcinoma converted by transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies: a multicenter retrospective study","volume":"12","author":"Wu","year":"2023","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2026.06.037_bib84","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41571-023-00760-3","article-title":"Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma","volume":"20","author":"Lucas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib85","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","article-title":"Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity","volume":"2","author":"Ho","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jhep.2026.06.037_bib86","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000529574","volume":"12","author":"Kudo","year":"2023","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2026.06.037_bib87","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/liv.15907","article-title":"Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab","volume":"44","author":"Kikuchi","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2026.06.037_bib88","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001725","article-title":"Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: a real-world study","author":"Tovoli","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.06.037_bib89","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005457","article-title":"Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study","volume":"10","author":"de la Torre-Alaez","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhep.2026.06.037_bib90","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","article-title":"Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial","volume":"8","author":"Chiang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.06.037_bib91","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.06.037_bib92","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.06.037_bib93","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31614","article-title":"Genomic analysis of vascular invasion in HCC reveals molecular drivers and predictive biomarkers","volume":"73","author":"Krishnan","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.06.037_bib94","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1245\/ASO.2006.08.007","article-title":"Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma","volume":"13","author":"Chen","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib95","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jamcollsurg.2005.11.012","article-title":"Prognostic index for patients with hepatocellular carcinoma combined with tumor thrombosis in the major portal vein","volume":"202","author":"Ikai","year":"2006","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib96","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1245\/s10434-010-0940-4","article-title":"Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus","volume":"17","author":"Shi","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib97","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/MEG.0b013e32834dda64","article-title":"Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein","volume":"24","author":"Liu","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.06.037_bib98","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jhep.2016.05.044","article-title":"Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion","volume":"65","author":"Kokudo","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.06.037_bib99","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s12072-024-10732-z","article-title":"APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024","volume":"18","author":"Lau","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2026.06.037_bib100","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00330-025-11882-w","article-title":"Yttrium-90 glass microsphere radioembolization as frontline treatment for hepatocellular carcinoma with localized portal vein invasion","volume":"36","author":"Choi","year":"2026","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jhep.2026.06.037_bib101","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.hpb.2021.12.013","article-title":"Conversion to resection post radioembolization in patients with HCC: recommendations from a multidisciplinary working group","volume":"24","author":"Baker","year":"2022","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jhep.2026.06.037_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2026.103884","article-title":"Effectiveness and safety of selective internal radiation therapy using yttrium-90 glass microspheres for hepatocellular carcinoma: real-world results from the multi-center prospective PROACTIF cohort of 989 patients","volume":"95","author":"Guiu","year":"2026","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jhep.2026.06.037_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.2099","article-title":"1469MO Liver resection versus continued atezolizumab plus bevacizumab (atezo\/bev) in locally advanced hepatocellular carcinoma (HCC) after atezo\/bev treatment (TALENTop): a multicenter, open-label, randomized phase III trial","volume":"36","author":"Sun","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib104","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2012.05.052","article-title":"Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria","volume":"143","author":"Duvoux","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.06.037_bib105","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma","volume":"154","author":"Mazzaferro","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.06.037_bib106","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1200\/JCO.2009.23.1282","article-title":"Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival","volume":"27","author":"Riaz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib107","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41416-023-02334-7","article-title":"Trajectories of alpha-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study","volume":"129","author":"Lu","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2026.06.037_bib108","article-title":"LBA11 - neoadjuvant toripalimab plus lenvatinib and GEMOX in resectable, high-risk intrahepatic cholangiocarcinoma: a randomized, multicenter","author":"Guoming Shi","year":"2025","journal-title":"open-label phase II-III clinical trial."},{"key":"10.1016\/j.jhep.2026.06.037_bib109","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1245\/s10434-023-13809-5","article-title":"NEO-GAP: a single-arm, phase II feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma","volume":"30","author":"Maithel","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib110","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/bjs.10676","article-title":"Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent","volume":"105","author":"Zhang","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.jhep.2026.06.037_bib111","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa2513918","article-title":"Neoadjuvant GOLP in resectable high-risk intrahepatic cholangiocarcinoma","volume":"394","author":"Shi","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.06.037_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1390","article-title":"97P Neoadjuvant durvalumab plus gemcitabine and cisplatin (D+GemCis) versus gemcis alone for localized biliary tract cancer (BTC): results of a randomized, multicenter, open-label, phase II trial (DEBATE)","volume":"34","author":"Yoo","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib113","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib114","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1470-2045(25)00376-6","article-title":"Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study","volume":"26","author":"Shi G","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib115","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","article-title":"Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial","volume":"6","author":"Edeline","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib116","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","article-title":"Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial","volume":"6","author":"Cercek","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib117","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1200\/JCO-25-00923","article-title":"Hepatic arterial infusion pump chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma-PUMP-2 trial","volume":"44","author":"Franssen","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib118","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.06.037_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104003","article-title":"ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer","volume":"10","author":"Vogel","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.jhep.2026.06.037_bib120","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic determinants of outcome in intrahepatic cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.06.037_bib121","series-title":"PROOF 301: results of an early discontinued randomized phase 3 trial of the oral FGFR inhibitor infigratinib vs. gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma (CCA) with an FGFR2 gene fusion\/rearrangement","author":"Abou-Alfa","year":"2024"},{"key":"10.1016\/j.jhep.2026.06.037_bib122","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/hep4.1730","article-title":"DNA methylation markers for detection of cholangiocarcinoma: discovery, validation, and clinical testing in biliary brushings and plasma","volume":"5","author":"Yang","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2026.06.037_bib123","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/s12072-022-10348-1","article-title":"Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies","volume":"16","author":"Fu","year":"2022","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2026.06.037_bib124","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004656","article-title":"Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial","volume":"10","author":"Xia","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhep.2026.06.037_bib125","article-title":"Prognostic value of postoperative circulating tumor DNA in patients with early- and intermediate-stage hepatocellular carcinoma","volume":"12","author":"Ye","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhep.2026.06.037_bib126","series-title":"The clinical landscape of cell-free DNA alterations in 1,671 patients with advanced biliary tract cancer","author":"Berchuck","year":"2022"},{"key":"10.1016\/j.jhep.2026.06.037_bib127","article-title":"Detecting early recurrence with circulating tumor DNA in stage I-III biliary tract cancer after curative resection","volume":"9","author":"Yu","year":"2025","journal-title":"JCO Precis Oncol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826027017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826027017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T16:54:36Z","timestamp":1789491276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826027017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":127,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0168827826027017"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.06.037","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pushing the boundaries of liver resection for liver cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.06.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}